R. Jungwirth

发表

Ceftazidime-Resistant EnterobacteriaceaeIsolates from Three Polish Hospitals: Identification of Three Novel TEM- and SHV-5-Type Extended-Spectrum β-Lactamases

W. Hryniewicz, M. Gniadkowski, A. Bauernfeind, 1998, Antimicrobial Agents and Chemotherapy.

Cefotaxime-Resistant EnterobacteriaceaeIsolates from a Hospital in Warsaw, Poland: Identification of a New CTX-M-3 Cefotaxime-Hydrolyzing β-Lactamase That Is Closely Related to the CTX-M-1/MEN-1 Enzyme

M. Gniadkowski, A. Bauernfeind, I. Schneider, 1998, Antimicrobial Agents and Chemotherapy.

Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis

A. Bauernfeind, G. Hörl, R. Bertele, 1987, Infection.

A Novel Type of AmpC β-Lactamase, ACC-1, Produced by a Klebsiella pneumoniae Strain Causing Nosocomial Pneumonia

U. Ullmann, H. Sahly, A. Bauernfeind, 1999, Antimicrobial Agents and Chemotherapy.

A novel class C beta-lactamase (FOX-2) in Escherichia coli conferring resistance to cephamycins

D. Meyer, A. Bauernfeind, I. Schneider, 1997, Antimicrobial agents and chemotherapy.

Comparative characterization of the cephamycinase blaCMY-1 gene and its relationship with other beta-lactamase genes

I. Stemplinger, A. Bauernfeind, R. Jungwirth, 1996, Antimicrobial agents and chemotherapy.

Characterization of the plasmidic beta-lactamase CMY-2, which is responsible for cephamycin resistance

I. Stemplinger, H. Giamarellou, A. Bauernfeind, 1996, Antimicrobial agents and chemotherapy.

Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil

A. Bauernfeind, R. Jungwirth, 1991, Infection.

Discrimination of Burkholderia multivorans and Burkholderia vietnamiensis fromBurkholderia cepacia Genomovars I, III, and IV by PCR

A. Bauernfeind, I. Schneider, R. Jungwirth, 1999, Journal of Clinical Microbiology.

Sequences of beta-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other beta-lactamases

I. Stemplinger, J. Casellas, A. Bauernfeind, 1996, Antimicrobial agents and chemotherapy.

Comparative Characterization of the Cephamycinasebla CMY-1 Gene and Its Relationship with Other b-Lactamase Genes

I. Stemplinger, A. Bauernfeind, R. Jungwirth, 1996 .

A Novel Type of AmpC β-Lactamase, ACC-1, Produced by a Klebsiella pneumoniae Strain Causing Nosocomial Pneumonia

U. Ullmann, H. Sahly, A. Bauernfeind, 1999, Antimicrobial Agents and Chemotherapy.

[Antibacterial activity and beta-lactamase stability of eleven oral cephalosporins].

A. Bauernfeind, S. Schweighart, R. Jungwirth, 1990, Infection.

Characterization of beta-lactamase gene blaPER-2, which encodes an extended-spectrum class A beta-lactamase

I. Stemplinger, J. Casellas, A. Bauernfeind, 1996, Antimicrobial agents and chemotherapy.

A new plasmidic cefotaximase from patients infected withSalmonella typhimurium

A. Bauernfeind, M. Goldberg, S. Schweighart, 1992, Infection.

RU 29 246, the active compound of the cephalosporin-prodrug-ester HR 916. I. Antibacterial activity in vitro.

A. Bauernfeind, G. Seibert, N. Klesel, 1992, The Journal of antibiotics.

Simultaneous simulation of the serum profiles of two antibiotics and analysis of the combined effect against a culture of Pseudomonas aeruginosa.

A. Bauernfeind, R. Jungwirth, C. Petermüller, 1982, Chemotherapy.

Discrimination of Burkholderia gladiolifrom Other Burkholderia Species Detectable in Cystic Fibrosis Patients by PCR

A. Bauernfeind, I. Schneider, R. Jungwirth, 1998, Journal of Clinical Microbiology.

In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE 2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin)

A. Bauernfeind, S. Schweighart, R. Jungwirth, 2005, Infection.

Escherichia coli producing a cephamycinase (CMY-2) from a patient from the Libyan---Tunisian border region.

R. Frei, A. Bauernfeind, I. Schneider, 1998, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

In-vitro activity of meropenem imipenem, the penem HRE 664 and ceftazidine against clinical isolates from West Germany.

A. Bauernfeind, S. Schweighart, R. Jungwirth, 1989, The Journal of antimicrobial chemotherapy.

Multiclonal emergence of ciprofloxacin-resistant clinical isolates of Escherichia coli and Klebsiella pneumoniae.

A. Bauernfeind, M. Abele-Horn, P. Emmerling, 1994, The Journal of antimicrobial chemotherapy.

Selection of antibiotics for treatment and prophylaxis of staphylococcal infections in cystic fibrosis patients

C. Matthias, A. Bauernfeind, R. Bertele, 1990, Infection.

Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens

A. Bauernfeind, R. Jungwirth, E. Eberlein, 1995, Infection.

Molecular Procedure for Rapid Detection ofBurkholderia mallei and Burkholderia pseudomallei

A. Bauernfeind, I. Schneider, R. Jungwirth, 1998, Journal of Clinical Microbiology.

Susceptibility of Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients to Ciprofloxacin

F. Ratjen, A. Bauernfeind, R. Jungwirth, 1999 .